A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 117
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : TC
Long Form : tumor cells
No. Year Title Co-occurring Abbreviation
2020 A biomechanical model for the transendothelial migration of cancer cells. ECs
2020 Correlation of PD-L1 expression on tumor cell and tumor infiltrating immune cell with 18F-fluorodeoxyglucose uptake on PET/computed tomography in surgically resected pulmonary adenocarcinoma. ADC, AUC, CT, F-FDG, IC, PD-L1
2020 Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead toward personalized treatment. CSS, ICs, pCR
2020 In silico models accurately predict in vivo response for IL-6 blockade in head and neck cancer. CSCs, EC, HNSCC, IL-6, TCZ
2020 Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma. BC, HSCC, IC, ICC, OPA, PD-L1, UC
2020 PD-L1 Expression and Tumor-infiltrating Lymphocytes in Breast Cancer: Clinicopathological Analysis in Women Younger than 40 Years Old. ER, IBC, IC, PD-L1, PDL1IC, PDL1TC, PR, TILs
2020 PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer. NSCLC, OS, TILs, TNBC
2020 Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA. EGFRm, PD-L1, PFS
2020 [Protein expression of PD-L1 and clinico-pathological data in a cohort of 53 patients with resectable non small cell lung cancer (NSCLC). Concordance between clones (22C3 and 28-8) and observers. Correlation and prognostic value of clinico-pathological data]. NSCLC
10  2019 Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNgamma signaling in non-small cell lung cancer. IC, NSCLC
11  2019 Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva. SQCV
12  2019 Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC). BCG, ER, IC, NMIBC
13  2019 Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non-Small Cell Lung Cancer. IC, PD-L1
14  2019 Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer. AGC, EBV, MMR, MMR-D, MMR-P, ORR, pts, TMB
15  2019 Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer. dMMR, EBV, IC, IHC, MGC, MMR, pts
16  2019 Comparability of PD-L1 immunohistochemistry assays for non-small cell lung cancer: a systematic review. LDTs, NSCLC, PD-L1
17  2019 Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma. DHL, DLBCL, FISH, IC, IHC, PD-L1, PMBCL
18  2019 Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma. CPS, IC, IHC, PD-1, UC
19  2019 Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab. IC, NSCLC, PD-L1, UC
20  2019 Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions. IC, ICI, UC
21  2019 Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naive Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival. EG, PD-1, PD-L1, TIC
22  2019 Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study. PD-L1
23  2019 irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. irORR, irPD, irPFS, irRECIST, irRECIST, mccRCC, ORR, PD, PFS, TIC
24  2019 Mismatch repair status and high expression of PD-L1 in nasopharyngeal carcinoma. dMMR, ICBs, MMR, NPC, TIIC
25  2019 Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. IC, PD-1, PD-L1
26  2019 Multiscale modeling of solid stress and tumor cell invasion in response to dynamic mechanical microenvironment. ---
27  2019 PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer. ACRG, GC, IC, IHC, MSI
28  2019 PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. mRCC, OS, PD-L1, PFS
29  2019 PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity. GEP, IC, IHC, NEC, NEN, NETs, PD-L1, TAIC
30  2019 PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies. BC, IC, ICB, UC
31  2019 PD-L1 Expression on Tumor Cells Is Associated With a Poor Outcome in a Cohort of Caucasian Nasopharyngeal Carcinoma Patients. CD8, DFS, LAG3, NPC, OS, PD-1, PD-L1, TILs
32  2019 PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression in pulmonary emphysema and chronic obstructive pulmonary disease with resected lung squamous cell carcinoma. COPD, GOLD, IC, IHC, SCC
33  2019 Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma. ICI, NSCLC, PD-L1
34  2019 Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma. HCC, IC, IHC, mAbs, PD-L1
35  2019 Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma. IC, LADC
36  2019 Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer. IC, PD-L1
37  2018 A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. IC, IC
38  2018 Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research. AR, OS, PD-L1
39  2018 Atezolizumab in Japanese Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study. CI, IC, ITT, NSCLC, OS, PD-L1
40  2018 CD73 expression and clinical significance in human metastatic melanoma. OS, TIMC
41  2018 Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients. ADC, IC, PD-1, PD-L1, SCC
42  2018 Classifying Non-Small Cell Lung Cancer by Status of Programmed Cell Death Ligand 1 and Tumor-Infiltrating Lymphocytes on Tumor Cells. IHC, PD-L1, TIL
43  2018 Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. BPH, CRPC, IC, PC
44  2018 Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples. IHC, NSCLCs, PD-L1
45  2018 FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC. IC, PD-L1
46  2018 PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. BP, BP2, ICC, PD-L1
47  2018 PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry. CGP, CRC, IC, ICPI, IHC, MMR-D, MMR-P, NSCLC
48  2018 Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma. CI, IC, OS, TIL
49  2018 RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer. IC
50  2018 TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. HNSCC, IC
51  2017 A Four-Factor Immunoscore System That Predicts Clinical Outcome for Stage II/III Gastric Cancer. AJCC, AUC, IC, OS, TNM
52  2017 Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer. IC, NPC
53  2017 Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: A report from India. IC, PD-L1
54  2017 Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer. EBUS-TBNA, IC, IHC, NSCLC, PD-L1
55  2017 Endothelial Notch1 Activity Facilitates Metastasis. ECs
56  2017 PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC). AD, NSCLC, SCC, TIL
57  2017 PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung. AC, IC, IT, NSCLC, PD-L1, SCC
58  2017 Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). IC, NSCLC, ORR, OS, PD-L1, RECIST
59  2017 Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancer. CI, DFS, HR, PD-L1, TIMC
60  2017 Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer. CI, IHC, NSCLC, PD-L1, TIL
61  2017 Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer. EGFR, IC, NSCLC, PD-L1
62  2017 Tumor cell PD-L1 predicts poor local control for rectal cancer patients following neoadjuvant radiotherapy. IC, LRFS, RT
63  2017 Tumor cells and their crosstalk with endothelial cells in 3D spheroids. EC, ECM
64  2017 Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. 5-year OS, IC, IF, pts, TILs, TMAs
65  2016 Chemotherapy-Induced Inflammatory Gene Signature and Protumorigenic Phenotype in Pancreatic CAFs via Stress-Associated MAPK. CAF, N-CAF, PDAC, SASP
66  2016 Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. IC, IHC, NSCLC, PD-L1
67  2016 High-density lipoprotein of patients with breast cancer complicated with type 2 diabetes mellitus promotes cancer cells adhesion to vascular endothelium via ICAM-1 and VCAM-1 upregulation. HDL, HUVECs, N-HDL, PKC, T2DM
68  2016 Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting. anti-PD-1, DC, NSCLC
69  2016 PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. AD, IC, IHC, NSCLC, SQ
70  2016 PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. HNSCC, IC, PD-L1, TILs
71  2015 Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment. DCs, OS
72  2015 High Jagged1 expression is associated with poor outcome in primary glioblastoma. EC, OS, TTP
73  2015 Localized Modeling of Biochemical and Flow Interactions during Cancer Cell Adhesion. CFD, PMN
74  2014 A tumor growth model with deformable ECM. ECM, HC, IF, MTS
75  2014 High-dose IL2 in metastatic melanoma: better survival in patients immunized with antigens from autologous tumor cell lines. ASI, IL-2
76  2013 A multiphase model for three-dimensional tumor growth. ECM, HC, IF, MTS, TCAT
77  2013 Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome. DTCs, HC, HR, ICC, QHC, UIC
78  2013 MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis. miRs, PDAC, TAFs
79  2013 Targeting combinations of liposomal drugs to both tumor vasculature cells and tumor cells for the treatment of HER2-positive breast cancer. HER2, TV
80  2012 Multidrug resistance proteins expression in glioma patients with epilepsy. AEDs, EC, GBM, GST-pi, HGG, LGG, MRPs, P-gp
81  2011 Rac1-regulated endothelial radiation response stimulates extravasation and metastasis that can be blocked by HMG-CoA reductase inhibitors. EC, IR, RT, TBI
82  2010 Generation and characterization of non-small-cell lung cancer cell lines and clones for use in the study of immunotherapy. NSCLC
83  2009 Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. AC, SCC
84  2009 Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report. DCs, GM-CSF, IL
85  2007 Antigen loading of dendritic cells with apoptotic tumor cell-preparations is superior to that using necrotic cells or tumor lysates. DCs, INF-gamma
86  2007 GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia. CTL
87  2007 [Chemoresistance of CD133(+) tumor stem cells from human brain glioma]. BTS, MACS, MDR, MDR1, MRP1, SFM, TSC
88  2006 Cancer dormancy: from mice to man. CTCs
89  2006 Generation of cell hybrids via a fusogenic cell line. DC, FMG, PEG
90  2004 Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling. CTL, DC, PBMC
91  2004 Role of tumor cell adhesion and migration in organ-specific metastasis formation. ---
92  2004 The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: evaluation of morphological categories and the number of clinically significant cells. BCD, BM, HCs, ICC, ITCs, SR, UIC
93  2004 [Experimental studies on anti-tumor effects of BLC-modified tumor cell vaccine combined with cisplatin]. s.c
94  2001 Influence of quercetin on B16 melanotic melanoma growth in C57BL/6 mice and on activity of some acid hydrolases in melanoma tissue. EM, QC
95  1999 Adenovirus p53 purging for human breast cancer stem cell products. AdV, PSC
96  1999 Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy. BC, HD, LPs
97  1999 Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. HC, ICC
98  1998 Growth curves: a method of monitoring established long-term primary human tumor cell cultures for autologous immunotherapy. ---
99  1998 Tumor-driven matrix invasion by infiltrating lymphocytes: involvement of the alpha1 integrin I-domain. MCP-1, TIL
100  1997 Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood. BM, ICC, IMS, mAb, MNC, PB